Claris ends litigation row with Fresenius Kabi over propofol injection

Claris Lifesicences Ltd has announced settlement of litigation and license agreement for its generic Diprivan in USA with Fresenius Kabi USA. “The company has reached a settlement and license agreement, ending all pending litigation with Fresenius Kabi USA, Inc. with reference to alleged infringement of a patent relating to propofol for injection, 10 mg/ml, which is a generic version of Diprivan,” said Claris Lifesicences in a press release.
 
As per the terms of the settlement and license agreement, Claris and Claris Lifesciences Inc (USA) has been granted approval to sell its generic version of propofol for injection beginning 15th October 2016, prior to June 1, 2025 expiry of the patent that formed the basis of the litigation.
 
According to IMS health data as of June 2014, propofol injection had an annual market size of approximately $ 251 million in the US.